Reovirus-mediated cytotoxicity and enhancement of innate immune responses against acute myeloid leukemia

Kathryn Hall, Karen J. Scott, Ailsa Rose, Michael Desborough, Kevin Harrington, Hardev Pandha, Christopher Parrish, Richard Geoffrey Vile, Matt Coffey, David Bowen, Fiona Errington-Mais, Alan A. Melcher

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Reovirus is a naturally occurring oncolytic virus that has shown preclinical efficacy in the treatment of a wide range of tumor types and has now reached phase III testing in clinical trials. The anti-cancer activity of reovirus has been attributed to both its direct oncolytic activity and the enhancement of anti-tumor immune responses. In this study, we have investigated the direct effect of reovirus on acute myeloid leukemia (AML) cells and its potential to enhance innate immune responses against AML, including the testing of primary samples from patients. Reovirus was found to replicate in and kill AML cell lines, and to reduce cell viability in primary AML samples. The pro-inflammatory cytokine interferon alpha (IFNα) and the chemokine (C-C motif) ligand 5 (known as RANTES [regulated upon activation, normal T-cell expressed, and secreted]) were also secreted from AML cells in response to virus treatment. In addition, reovirus-mediated activation of natural killer (NK) cells, within the context of peripheral blood mononuclear cells, stimulated their anti-leukemia response, with increased NK degranulation and IFNc production and enhanced killing of AML targets. These data suggest that reovirus has the potential as both a direct cytotoxic and an immunotherapeutic agent for the treatment of AML.

Original languageEnglish (US)
Pages (from-to)3-15
Number of pages13
JournalBioResearch Open Access
Volume1
Issue number1
DOIs
StatePublished - Jan 1 2012

Fingerprint

Cytotoxicity
Viruses
Innate Immunity
Acute Myeloid Leukemia
Tumors
Chemical activation
Cells
CXC Chemokines
T-cells
Cytotoxins
Testing
Interferon-alpha
Myeloid Cells
Blood
Cytokines
Ligands
Oncolytic Viruses
Neoplasms
Natural Killer Cells
Blood Cells

Keywords

  • Acute myeloid leukemia
  • Immunotherapy
  • NK cells
  • Oncolytic virus
  • Reovirus

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Hall, K., Scott, K. J., Rose, A., Desborough, M., Harrington, K., Pandha, H., ... Melcher, A. A. (2012). Reovirus-mediated cytotoxicity and enhancement of innate immune responses against acute myeloid leukemia. BioResearch Open Access, 1(1), 3-15. https://doi.org/10.1089/biores.2012.0205

Reovirus-mediated cytotoxicity and enhancement of innate immune responses against acute myeloid leukemia. / Hall, Kathryn; Scott, Karen J.; Rose, Ailsa; Desborough, Michael; Harrington, Kevin; Pandha, Hardev; Parrish, Christopher; Vile, Richard Geoffrey; Coffey, Matt; Bowen, David; Errington-Mais, Fiona; Melcher, Alan A.

In: BioResearch Open Access, Vol. 1, No. 1, 01.01.2012, p. 3-15.

Research output: Contribution to journalArticle

Hall, K, Scott, KJ, Rose, A, Desborough, M, Harrington, K, Pandha, H, Parrish, C, Vile, RG, Coffey, M, Bowen, D, Errington-Mais, F & Melcher, AA 2012, 'Reovirus-mediated cytotoxicity and enhancement of innate immune responses against acute myeloid leukemia', BioResearch Open Access, vol. 1, no. 1, pp. 3-15. https://doi.org/10.1089/biores.2012.0205
Hall, Kathryn ; Scott, Karen J. ; Rose, Ailsa ; Desborough, Michael ; Harrington, Kevin ; Pandha, Hardev ; Parrish, Christopher ; Vile, Richard Geoffrey ; Coffey, Matt ; Bowen, David ; Errington-Mais, Fiona ; Melcher, Alan A. / Reovirus-mediated cytotoxicity and enhancement of innate immune responses against acute myeloid leukemia. In: BioResearch Open Access. 2012 ; Vol. 1, No. 1. pp. 3-15.
@article{16231f2d489a4612b1808ae9159f651e,
title = "Reovirus-mediated cytotoxicity and enhancement of innate immune responses against acute myeloid leukemia",
abstract = "Reovirus is a naturally occurring oncolytic virus that has shown preclinical efficacy in the treatment of a wide range of tumor types and has now reached phase III testing in clinical trials. The anti-cancer activity of reovirus has been attributed to both its direct oncolytic activity and the enhancement of anti-tumor immune responses. In this study, we have investigated the direct effect of reovirus on acute myeloid leukemia (AML) cells and its potential to enhance innate immune responses against AML, including the testing of primary samples from patients. Reovirus was found to replicate in and kill AML cell lines, and to reduce cell viability in primary AML samples. The pro-inflammatory cytokine interferon alpha (IFNα) and the chemokine (C-C motif) ligand 5 (known as RANTES [regulated upon activation, normal T-cell expressed, and secreted]) were also secreted from AML cells in response to virus treatment. In addition, reovirus-mediated activation of natural killer (NK) cells, within the context of peripheral blood mononuclear cells, stimulated their anti-leukemia response, with increased NK degranulation and IFNc production and enhanced killing of AML targets. These data suggest that reovirus has the potential as both a direct cytotoxic and an immunotherapeutic agent for the treatment of AML.",
keywords = "Acute myeloid leukemia, Immunotherapy, NK cells, Oncolytic virus, Reovirus",
author = "Kathryn Hall and Scott, {Karen J.} and Ailsa Rose and Michael Desborough and Kevin Harrington and Hardev Pandha and Christopher Parrish and Vile, {Richard Geoffrey} and Matt Coffey and David Bowen and Fiona Errington-Mais and Melcher, {Alan A.}",
year = "2012",
month = "1",
day = "1",
doi = "10.1089/biores.2012.0205",
language = "English (US)",
volume = "1",
pages = "3--15",
journal = "BioResearch Open Access",
issn = "2164-7860",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - Reovirus-mediated cytotoxicity and enhancement of innate immune responses against acute myeloid leukemia

AU - Hall, Kathryn

AU - Scott, Karen J.

AU - Rose, Ailsa

AU - Desborough, Michael

AU - Harrington, Kevin

AU - Pandha, Hardev

AU - Parrish, Christopher

AU - Vile, Richard Geoffrey

AU - Coffey, Matt

AU - Bowen, David

AU - Errington-Mais, Fiona

AU - Melcher, Alan A.

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Reovirus is a naturally occurring oncolytic virus that has shown preclinical efficacy in the treatment of a wide range of tumor types and has now reached phase III testing in clinical trials. The anti-cancer activity of reovirus has been attributed to both its direct oncolytic activity and the enhancement of anti-tumor immune responses. In this study, we have investigated the direct effect of reovirus on acute myeloid leukemia (AML) cells and its potential to enhance innate immune responses against AML, including the testing of primary samples from patients. Reovirus was found to replicate in and kill AML cell lines, and to reduce cell viability in primary AML samples. The pro-inflammatory cytokine interferon alpha (IFNα) and the chemokine (C-C motif) ligand 5 (known as RANTES [regulated upon activation, normal T-cell expressed, and secreted]) were also secreted from AML cells in response to virus treatment. In addition, reovirus-mediated activation of natural killer (NK) cells, within the context of peripheral blood mononuclear cells, stimulated their anti-leukemia response, with increased NK degranulation and IFNc production and enhanced killing of AML targets. These data suggest that reovirus has the potential as both a direct cytotoxic and an immunotherapeutic agent for the treatment of AML.

AB - Reovirus is a naturally occurring oncolytic virus that has shown preclinical efficacy in the treatment of a wide range of tumor types and has now reached phase III testing in clinical trials. The anti-cancer activity of reovirus has been attributed to both its direct oncolytic activity and the enhancement of anti-tumor immune responses. In this study, we have investigated the direct effect of reovirus on acute myeloid leukemia (AML) cells and its potential to enhance innate immune responses against AML, including the testing of primary samples from patients. Reovirus was found to replicate in and kill AML cell lines, and to reduce cell viability in primary AML samples. The pro-inflammatory cytokine interferon alpha (IFNα) and the chemokine (C-C motif) ligand 5 (known as RANTES [regulated upon activation, normal T-cell expressed, and secreted]) were also secreted from AML cells in response to virus treatment. In addition, reovirus-mediated activation of natural killer (NK) cells, within the context of peripheral blood mononuclear cells, stimulated their anti-leukemia response, with increased NK degranulation and IFNc production and enhanced killing of AML targets. These data suggest that reovirus has the potential as both a direct cytotoxic and an immunotherapeutic agent for the treatment of AML.

KW - Acute myeloid leukemia

KW - Immunotherapy

KW - NK cells

KW - Oncolytic virus

KW - Reovirus

UR - http://www.scopus.com/inward/record.url?scp=84923643407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923643407&partnerID=8YFLogxK

U2 - 10.1089/biores.2012.0205

DO - 10.1089/biores.2012.0205

M3 - Article

AN - SCOPUS:84923643407

VL - 1

SP - 3

EP - 15

JO - BioResearch Open Access

JF - BioResearch Open Access

SN - 2164-7860

IS - 1

ER -